American Journal of Kidney Diseases
Volume 45, Issue 3 , Pages 473-484, March 2005

First United Kingdom Heart and Renal Protection (UK-HARP-I) study: Biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease

  • Colin Baigent, BMBCh

      Affiliations

    • Clinical Trial Service Unit, Oxford University, Oxford, UK
    • Corresponding Author InformationAddress reprint requests to Colin Baigent, BMBCh, Clinical Trial Service Unit, Radcliffe Infirmary, Oxford OX2 6HE, UK.
    • ,
  • Martin Landray, MD, PhD

      Affiliations

    • Clinical Trial Service Unit, Oxford University, Oxford, UK
    • ,
  • Craig Leaper, PhD

      Affiliations

    • Clinical Trial Service Unit, Oxford University, Oxford, UK
    • ,
  • Paul Altmann, MD (FRCP)

      Affiliations

    • Churchill Hospital, Oxford, UK
    • ,
  • Jane Armitage, MBBS, MFPH

      Affiliations

    • Clinical Trial Service Unit, Oxford University, Oxford, UK
    • ,
  • Alex Baxter, MA

      Affiliations

    • Clinical Trial Service Unit, Oxford University, Oxford, UK
    • ,
  • Hugh S. Cairns, MD

      Affiliations

    • Kings College Hospital, London, UK
    • ,
  • Rory Collins (FMedSci)

      Affiliations

    • Clinical Trial Service Unit, Oxford University, Oxford, UK
    • ,
  • Robert N. Foley, MB, MSc

      Affiliations

    • Hope Hospital, Salford, UK
    • ,
  • Valeria Frighi, MD

      Affiliations

    • Clinical Trial Service Unit, Oxford University, Oxford, UK
    • ,
  • Karen Kourellias

      Affiliations

    • Clinical Trial Service Unit, Oxford University, Oxford, UK
    • ,
  • Peter J. Ratcliffe (FRS)

      Affiliations

    • Churchill Hospital, Oxford, UK
    • ,
  • Mary Rogerson, MD (FRCP)

      Affiliations

    • Southampton General Hospital, Southampton, UK
    • ,
  • John E. Scoble, MD (FRCP)

      Affiliations

    • Guy’s Hospital, London, UK
    • ,
  • Charles R.V. Tomson, DM

      Affiliations

    • Southmead Hospital, Bristol, UK.
    • ,
  • David C. Wheeler, MD (FRCP)

      Affiliations

    • Royal Free Hospital, London, UK

Received 29 July 2004; accepted 9 November 2004. published online 25 January 2005.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 The HARP pilot studies and the Study of Heart and Renal Protection (SHARP) were funded by unrestricted grants from Merck & Co. C.B., M.L., J.A., and R.C. each received reimbursement from Merck for travel expenses in connection with various speaking engagements, but as members of the Clinical Trial Service Unit, comply with the Unit’s policy of not accepting honoraria. See Appendix for UK-HARP Pilot Study Investigators.

 Originally published online as doi:10.1053/j.ajkd.2004.11.015 on January 25, 2005.

PII: S0272-6386(04)01596-3

doi:10.1053/j.ajkd.2004.11.015

American Journal of Kidney Diseases
Volume 45, Issue 3 , Pages 473-484, March 2005

Article Tools